WillScot Mobile Mini Reports Fourth Quarter and Full Year 2022 Results 22-02-2023, 04:01

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Meltwater Shareholders Vote “FOR” MW Investment B.V. Voluntary Offer 27-04-2023, 05:32